Emgality®: a once-monthly preventive treatment for patients with episodic or chronic migraine1

MHD=migraine headache day.

View additional data for patients with migraine, including results from a 12-month, open-label safety study, and the CONQUER study

References:

  1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
  2. García-Azorín D, Ford J, Buse DC, et al. Changes in work productivity and interictal burden: results from randomized, double-blind study evaluating galcanezumab in adults with treatment resistant migraine (CONQUER). Presented at: 17th Asian Oceanian Congress of Neurology (AOCN 2021); Taipei, Taiwan; April 1-4, 2021.
  3. Buse DC, Rupnow MF, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84:422-435.
  4. Lipton R, Stewart W, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646-657.
  5. Data on File. Lilly USA, LLC. DOF-GZ-US-0179.
  6. Mulleners WM, Kim BK, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19:814-825.
  7. Data on File. Lilly USA, LLC. DOF-GZ-US-0002.
  8. Bangs ME, Kudrow D, Wang S, et al. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurol. 2020;20:90. doi:10.1186/s12883-020-1609-7.
  9. Data on File. Lilly USA, LLC. DOF-GZ-US-0107.
  10. Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine. BMC Neurol. 2018;18(1):188. doi:10.1186/s12883-018-1193-2.
  11. Data on File. Lilly USA, LLC. DOF-GZ-US-0137.
  12. Data on File. Lilly USA, LLC. DOF-GZ-US-0139.
  13. Ailani J, Burch RC, Robbins MS; the Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;00:1-19.
  14. Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52:930-945.
  15. Data on File. Lilly USA, LLC. DOF-GZ-US-0060.
  16. Data on File. Lilly USA, LLC. DOF-GZ-US-0111.
  17. Data on File. Lilly USA, LLC. DOF-GZ-US-0181.
  18. Data on File. Lilly USA, LLC. DOF-GZ-US-0186.
  19. Data on File. Lilly USA, LLC. DOF-GZ-US-0120.

INDICATIONS

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

GZ HCP ISI 10DEC2019